Ghodasra Devon H, Demirci Hakan
Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan.
Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan.
Am J Ophthalmol. 2016 Jan;161:104-9.e1-2. doi: 10.1016/j.ajo.2015.09.033. Epub 2015 Oct 23.
To evaluate the effectiveness of photodynamic therapy (PDT) in the management of choroidal metastasis.
Retrospective, interventional case series.
Patients with choroidal metastasis treated with PDT at a single institution were reviewed. PDT was applied with verteporfin at a dose of 6 mg/m(2) body surface area and a 689 nm diode laser for 83 seconds. Visual acuity, tumor basal diameter, tumor thickness by ultrasonography, and enhanced depth imaging optical coherence tomography (EDI-OCT), as well as associated features including subretinal fluid, were recorded before PDT and during follow-up examinations.
Twenty-one tumors in 13 eyes of 10 patients were included. Eight tumors were treated with a single session of PDT, 11 tumors received 2 sessions, 1 tumor received 3 sessions, and 1 tumor received 5 sessions. At the end of a mean follow-up of 12 months (range, 3-42 months), 9 eyes (69%) had stable or improved visual acuity, while 4 eyes (31%) had decreased visual acuity. Mean logMAR change in visual acuity was -0.09 (range, -1.3 to 0.8). Seventeen of 21 tumors (81%) were flat at last follow-up. The mean decrease in ultrasound-measured thickness was 0.83 mm (range, 2.6 mm decrease to 1.4 mm increase), while the decrease in EDI-OCT-measured thickness was 400 μm (range, 1280 μm decrease to 280 μm increase). Eighteen tumors (86%) had complete resolution of subretinal fluid. There were no PDT-related complications.
Photodynamic therapy may be an effective therapeutic option for the management of choroidal metastasis in selected cases.
评估光动力疗法(PDT)治疗脉络膜转移瘤的有效性。
回顾性、介入性病例系列研究。
对在单一机构接受PDT治疗的脉络膜转移瘤患者进行回顾性分析。使用维替泊芬,以6 mg/m²体表面积的剂量及689 nm二极管激光进行83秒的PDT治疗。在PDT治疗前及随访检查期间记录视力、肿瘤基底直径、超声测量的肿瘤厚度、增强深度成像光学相干断层扫描(EDI-OCT)以及包括视网膜下液在内的相关特征。
纳入10例患者13只眼中的21个肿瘤。8个肿瘤接受单次PDT治疗,11个肿瘤接受2次治疗,1个肿瘤接受3次治疗,1个肿瘤接受5次治疗。平均随访12个月(范围3 - 42个月)结束时,9只眼(69%)视力稳定或提高,4只眼(31%)视力下降。视力的平均logMAR变化为-0.09(范围-1.3至0.8)。21个肿瘤中有17个(81%)在最后一次随访时变平。超声测量的厚度平均减少0.83 mm(范围从减少2.6 mm至增加1.4 mm),而EDI-OCT测量的厚度减少400 μm(范围从减少1280 μm至增加280 μm)。18个肿瘤(86%)的视网膜下液完全消退。未出现与PDT相关的并发症。
在特定病例中,光动力疗法可能是治疗脉络膜转移瘤的有效治疗选择。